Ocular Therapeutix Inc (NASDAQ:OCUL) shares are trading lower by 13.3% to $7.63 Monday afternoon after the company reported worse-than-expected first-quarter financial results.

What To Know: Ocular Therapeutix reported first-quarter 2025 results that missed analyst expectations on both earnings and revenue. The company posted a net loss of 38 cents per share, wider than the consensus estimate of a 29 cent loss.

Revenue fell 27.6% year-over-year to $10.7 million, significantly below the $16.83 million estimate, driven by lower DEXTENZA sales due to pricing impacts and changes in buying patterns across key healthcare settings.

Read Also: Airline Stocks Climb As Oil Prices Drop On OPEC+ Output Hike

Despite financial setbacks, Ocular highlighted progress in its AXPAXLI clinical programs. Phase 3 trials SOL-1 and SOL-R for wet age-related macular degeneration are advancing, with the FDA accepting key amendments that may support a six–12 month dosing regimen.

SOL-1 topline data remains on track for first-quarter 2026. The company also received favorable FDA feedback on a potential registrational trial for non-proliferative diabetic retinopathy.

What Else: Ocular ended the quarter with $349.7 million in cash, projecting runway into 2028. Operating expenses rose due to increased clinical activity and pre-commercialization efforts for AXPAXLI.

The company says it anticipates revenue improvements later in 2025 as market dynamics stabilize.

Read Also: Apple Stock Slides As Tariff Costs Mount, Bond Sale Planned

How To Buy OCUL Stock

Besides going to a brokerage platform to purchase a share — or fractional share — of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.

For example, in Ocular Therapeutix’s case, it is in the health care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.

According to data from Benzinga Pro, OCUL has a 52-week high of $11.77 and a 52-week low of $4.79.

Read Next:
• Palantir Smokes S&P 500 Peers With 393% Rally But Overheated Technicals Raise Red Flag Ahead Of Earnings

Photo: New Africa via Shutterstock